# PT-141 vs Apomorphine: Two Brain-Based Approaches Compared

**By TelosRX Editorial Team** · 2026-10-11

**PT-141 vs apomorphine comes down to two different brain pathways. PT-141 (bremelanotide) activates melanocortin receptors and was approved as Vyleesi for low sexual desire in premenopausal women, while apomorphine is a dopamine agonist that was studied for erectile dysfunction and is FDA-approved in the US only for Parkinson's disease. Both act centrally, but they differ in target, approval status and side effects.**

Most people comparing sexual health treatments start with blood-flow pills. These two belong to a smaller group that works in the brain instead. This guide explains how each one works, where each stands with regulators, what the research reported on side effects, and why telos rx prescribes one and not the other.

## Why compare PT-141 vs apomorphine at all?

Interest in apomorphine has climbed sharply in recent months, often from people who already know about PT-141 and want to understand the other "brain-based" option they keep seeing mentioned.

The comparison makes sense on paper. Both drugs act in the central nervous system rather than on the blood vessels of the genitals. Both were developed, at some point, with sexual function in mind. Beyond that, the similarities run out quickly.

If you are weighing blood-flow medicines such as tadalafil (Cialis) instead, that is a separate question, covered in [PT-141 vs Viagra and Cialis](https://www.telosrx.com/blogs/peptides/pt-141-vs-viagra-cialis).

## How apomorphine works

Apomorphine is a dopamine agonist. It stimulates dopamine receptors directly, which is why it is useful in Parkinson's disease, a condition defined by low dopamine signalling in the brain.

Dopamine also helps control erections. A [2002 review in the International Journal of Impotence Research](https://pubmed.ncbi.nlm.nih.gov/11850736/) (PMID 11850736) described apomorphine as the first erectile dysfunction drug to act through the central nervous system, with its pro-erectile effect coming from the brain and spinal cord rather than the penis itself.

That same review made a point that matters for this comparison: **no change in sexual desire was observed with apomorphine**. Its effect in the research was on the erectile response, not on wanting sex in the first place.

## How PT-141 works

PT-141 is the research name for bremelanotide, a synthetic peptide in the melanocortin family. It activates melanocortin receptors, mainly MC3R and MC4R, in brain regions linked to sexual motivation and arousal.

It is not a blood-flow drug and it does not act on dopamine receptors directly. Its development focused on desire itself, which is the clearest functional difference between the two. For the full receptor story, see [how PT-141 works](https://www.telosrx.com/blogs/glp1/pt-141-how-it-works), or start with the hub guide, [what is PT-141](https://www.telosrx.com/blogs/peptides/what-is-pt-141-bremelanotide-guide).

## PT-141 vs apomorphine: side by side

| Feature | PT-141 (bremelanotide) | Apomorphine |
| --- | --- | --- |
| **Drug type** | Synthetic peptide | Small-molecule dopamine agonist |
| **Main target** | Melanocortin receptors (MC3R and MC4R) in the brain | Dopamine receptors in the brain and spinal cord |
| **What it was studied for in sexual health** | Low sexual desire (HSDD) in premenopausal women | Erectile dysfunction in men |
| **Current US approval** | Vyleesi: acquired, generalized HSDD in premenopausal women only | Parkinson's disease off episodes (Apokyn injection), not sexual dysfunction |
| **Sexual health approval anywhere** | Yes, Vyleesi in the US since 2019 | Uprima in the EU from 2001 until its authorisation expired in 2006 |
| **Route in the sexual health research** | Subcutaneous injection | Sublingual tablet |
| **Most common side effect reported** | Nausea | Nausea |
| **Key safety flags** | Transient blood pressure rise, flushing, headache, skin darkening with repeated use | Fainting, low blood pressure, sleepiness, interaction with ondansetron-type drugs |
| **Use in men** | Off-label | Not approved for sexual use in the US |

## Approval status: where each drug stands

### Apomorphine

In the United States, apomorphine is approved for Parkinson's disease, not for any form of sexual dysfunction. The FDA approved [Apokyn (apomorphine injection)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021264) in 2004 for the acute, intermittent treatment of off episodes in advanced Parkinson's disease. A sublingual film for off episodes, Kynmobi, was approved in 2020 and is now listed by the FDA as discontinued. Another subcutaneous apomorphine product for Parkinson's, Onapgo, was approved in 2025.

The erectile dysfunction story happened mainly in Europe. According to the [European Medicines Agency](https://www.ema.europa.eu/en/medicines/human/EPAR/uprima), the European Commission authorised Uprima, a sublingual apomorphine tablet for men with erectile dysfunction, in May 2001. It was marketed in a handful of countries including the UK, Ireland, Spain and France. The holder did not renew the authorisation, citing commercial reasons, and it expired in May 2006.

So apomorphine for sexual health is, today, a chapter in the history of centrally acting treatments rather than a current US option.

### PT-141

The FDA approved Vyleesi (bremelanotide injection) in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is its only approved indication. Use in men is off-label, and any decision about it belongs to a licensed provider.

The approval rested on the two [RECONNECT phase 3 trials](https://pubmed.ncbi.nlm.nih.gov/31599840/) (Kingsberg et al., 2019, PMID 31599840). The Vyleesi label describes a 1.75 mg subcutaneous autoinjector used at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses a month. Those are the terms of the approved product, not instructions for compounded use.

Compounded PT-141 is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness or quality. With compounded PT-141, the prescribing provider sets the dose.

Curious whether a desire-focused option like PT-141 fits your health history? The online visit is reviewed by a licensed provider without a scheduled appointment, and you pay nothing if you are not approved.

[See if PT-141 is right for you](https://www.telosrx.com/pages/lp7pt141)

## Side effects: where the profiles differ

Nausea is the shared headline. After that, the two drugs carry different safety questions.

### Apomorphine in the erectile dysfunction research

In a [trial of 569 men](https://pubmed.ncbi.nlm.nih.gov/10869641/) (Dula et al., 2000, PMID 10869641), nausea was the most common side effect. It was dose related and eased over the course of the study. A [safety summary covering more than 5,000 patients](https://pubmed.ncbi.nlm.nih.gov/11477491/) (Bukofzer and Livesey, 2001, PMID 11477491) listed nausea, headache and dizziness as the most common effects, and noted that fainting (syncope) could occur at higher doses but was rare at approved doses.

### Apomorphine as a Parkinson's medicine

The doses used for Parkinson's are a different matter. The US label for apomorphine injection warns of severe nausea and vomiting at recommended doses, and it is contraindicated with ondansetron-type anti-nausea drugs because of reports of profound low blood pressure and loss of consciousness. Labeled warnings also include sudden sleepiness, fainting, falls, hallucinations and impulse-control problems.

### PT-141

In the 52-week [RECONNECT open-label extension](https://pubmed.ncbi.nlm.nih.gov/31599847/) (Simon et al., 2019, PMID 31599847), the most common treatment-related effects were nausea (40.4%), flushing (20.6%) and headache (12.0%). Bremelanotide also causes a transient rise in blood pressure with a modest drop in heart rate, and the trials excluded people with uncontrolled high blood pressure or known cardiovascular disease. Injection-site reactions and focal skin darkening with repeated dosing have also been reported.

The detail is in [PT-141 side effects and safety](https://www.telosrx.com/blogs/peptides/pt-141-side-effects-safety) and [who should not take PT-141](https://www.telosrx.com/blogs/glp1/pt-141-who-should-not-take-it).

## The real difference: desire vs the erectile response

Strip away the history and the comparison is about what each drug targets.

-   **Apomorphine** was studied for the erectile response in men, through dopamine signalling. The review literature did not find a change in desire.
-   **PT-141** was studied for low sexual desire in premenopausal women, through melanocortin signalling. In men it is off-label.

Neither is a general "libido booster", and neither is right for everyone. Which pathway, if any, fits your situation depends on your symptoms, your blood pressure, your other medicines and your history. That is a provider's call.

PT-141 is not the only melanocortin or hormone-adjacent option people ask about. Our planned comparisons of [PT-141 vs melanotan 2](https://www.telosrx.com/blogs/peptides/pt-141-vs-melanotan-2) and [PT-141 vs oxytocin](https://www.telosrx.com/blogs/peptides/pt-141-vs-oxytocin) cover those questions.

## Why telos rx prescribes PT-141 and not apomorphine

telos rx focuses on sexual desire and arousal. Bremelanotide is the centrally acting molecule with an FDA-approved sexual health indication (in premenopausal women) and published phase 3 data behind it. Apomorphine, in the US, is a Parkinson's medicine with a heavier safety label, and its sexual health authorisation in Europe lapsed years ago. telos rx does not prescribe apomorphine.

Here is how PT-141 works with telos rx:

1.  **Short online intake.** One intake for adults of any sex, covering your health history, blood pressure and medications.
2.  **Asynchronous provider review.** A licensed provider reviews it without a scheduled appointment. Every prescription is subject to medical approval by a licensed provider, and you pay nothing if you are not approved.
3.  **Licensed US partner pharmacy.** Compounded PT-141 is prescribed as a small as-needed subcutaneous injection given at home before anticipated activity, with free, discreet shipping.

Plans are as low as $138 per month, FSA/HSA eligible and can be cancelled anytime. telos rx is LegitScript-certified. telos rx does not offer a nasal spray. Full details are on the [PT-141 page](https://www.telosrx.com/pages/pt-141).

## Frequently asked questions

### Is PT-141 the same as apomorphine?

No. PT-141 (bremelanotide) is a peptide that activates melanocortin receptors in the brain. Apomorphine is a small molecule that stimulates dopamine receptors. Both act centrally rather than on blood flow, but they are different drugs with different approvals and different side-effect profiles.

### Is apomorphine FDA-approved for erectile dysfunction?

No. In the US, apomorphine is FDA-approved for Parkinson's disease, as Apokyn injection for acute off episodes. A sublingual apomorphine tablet called Uprima was authorised for erectile dysfunction in the European Union in 2001, and that authorisation expired in 2006 after it was not renewed.

### Is PT-141 FDA-approved for men?

No. The only FDA-approved bremelanotide product is Vyleesi, approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Use in men is off-label. Compounded PT-141 is not FDA-approved.

### Does apomorphine increase sexual desire?

That is not what the erectile dysfunction research showed. A 2002 review of sublingual apomorphine reported that no change in sexual desire was observed. Its studied effect in men was on the erectile response, while bremelanotide was studied for low sexual desire.

### What are the main side effects of apomorphine compared with PT-141?

Both commonly cause nausea. Apomorphine labeling also warns about low blood pressure, fainting, sudden sleepiness and a dangerous interaction with ondansetron-type anti-nausea drugs. Bremelanotide trials reported nausea, flushing and headache, plus a transient rise in blood pressure.

### Why does telos rx prescribe PT-141 and not apomorphine?

telos rx focuses on sexual desire and arousal, which is the area bremelanotide was studied and approved for in premenopausal women. Apomorphine is a Parkinson's medication in the US. Every PT-141 prescription is subject to medical approval by a licensed provider.

If low desire is the part that has changed, a short online visit is the simplest way to find out whether PT-141 is an option for you.

[Start your online visit](https://www.telosrx.com/pages/lp7pt141)

_This article is for general education and is not medical advice. Compounded PT-141 is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness or quality. Vyleesi is FDA-approved only for acquired, generalized HSDD in premenopausal women; use in men is off-label. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service and is LegitScript-certified. Medications are filled by licensed US partner pharmacies._

**Tags:** Apomorphine, Bremelanotide, Comparison, PT-141, Sexual Health

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/pt-141-vs-apomorphine)
